上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
PF-04217903 phenolsulfonate
PF-04217903 phenolsulfonate 是一种高效的 ATP 竞争性 c-Met 激酶抑制剂,Ki 为 4.8 nM。PF-04217903 phenolsulfonate 相对于 208 个激酶显示出 1000 倍以上的选择性。具有抗血管生成特性。
PF-04217903 phenolsulfonate Chemical Structure
CAS No. : 1159490-85-3
规格 |
|
是否有货 |
|
100 mg |
|
询价 |
|
250 mg |
|
询价 |
|
500 mg |
|
询价 |
|
* Please select Quantity before adding items.
PF-04217903 phenolsulfonate 的其他形式现货产品:
PF-04217903 PF-04217903 methanesulfonate
生物活性 |
PF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties[1][2].
|
IC50 & Target |
Ki: 4.8 nM (human c-Met)[1]
|
体外研究 (In Vitro) |
PF-04217903 phenolsulfonate (0.1-10000 nM; 48-72 hours) inhibits proliferation of c-Met–amplified human GTL-16 gastric carcinoma and H1993 NSCLC cells with IC50 values of 12 and 30 nM, respectively[1]. PF-04217903 phenolsulfonate (1.5-3333 nM; 48 hours) induces apoptosis of GTL-16 cells (IC50=31 nM)[1]. PF-04217903 phenolsulfonate also inhibits HGF-mediated cell migration and Matrigel invasion in several c-Met–overexpressing tumor cell lines such as human NCI-H441 lung carcinoma and HT29 colon carcinoma with IC50 values comparable with those for inhibition of c-Met phosphorylation in these cell lines (IC50=7-12.5 nM)[1]. PF-04217903 phenolsulfonate displays similar potency to inhibit the activity of c-Met-H1094R, c-Met-R988C, and c-Met-T1010I with IC50 of 3.1 nM, 6.4 nM, and 6.7 nM, respectively. PF-04217903 phenolsulfonate has no inhibitory activity against c-Met-Y1230C with IC50 of >10 μM[3].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay[1]
Cell Line: |
GTL-16, H1993 cells |
Concentration: |
0.1, 1, 10, 100, 1000, 10000 nM |
Incubation Time: |
48-72 hours |
Result: |
Inhibited proliferation of c-Met–amplified human GTL-16 gastric carcinoma and H1993 NSCLC cells with IC50 values of 12 and 30 nM, respectively. |
Apoptosis Analysis[1]
Cell Line: |
GTL-16 cells |
Concentration: |
1.5-3333 nM |
Incubation Time: |
48 hours |
Result: |
Induced apoptosis of GTL-16 cells. |
|
体内研究 (In Vivo) |
PF-04217903 phenolsulfonate (1-30 mg/kg; p.o.; daily for 16 days) shows dose-dependent tumor growth inhibition, which correlated with the inhibition in c-Met phosphorylation in these tumors[1]. PF-04217903 phenolsulfonate (5-50 mg/kg, p.o.; once daily for 3 days) dose dependently inhibits c-Met, Gab-1, Erk1/2, and AKT phosphorylation and induced apoptosis (cleaved caspase-3) in U87MG xenograft tumors at all dose levels. PF-04217903 phenolsulfonate shows a significant dose-dependent reduction of human IL-8 levels in both the U87MG and GTL-16 models and decreases human VEGFA levels in the GTL-16 model. PF-04217903 phenolsulfonate strongly induces phospho-PDGFRβ levels in U87MG xenograft tumors[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: |
Female nu/nu mice (GTL-16 xenograft model)[1] |
Dosage: |
1, 3, 10, 30 mg/kg |
Administration: |
Oral; daily for 16 days |
Result: |
Showed dose-dependent tumor growth inhibition, and was correlated with the inhibition in c-Met phosphorylation in these tumors. |
|
Clinical Trial |
|
分子量 |
|
Formula |
|
CAS 号 |
|
运输条件 |
Room temperature in continental US; may vary elsewhere.
|
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
参考文献 |
-
[1]. Zou HY, et al. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47.
[2]. Cui JJ, et al. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer. J Med Chem. 2012 Sep 27;55(18):8091-109.
[3]. Timofeevski SL, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry. 2009 Jun 16;48(23):5339-49.
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务